Wednesday, December 06, 2017 10:56:31 AM
They sell every spike, UNTIL
THE REALLLY BIG MONEY BUYS IN SIZE UPON REALIZATION (PROOF) CLRB IS THE REAL DEAL. FOR EXAMPLE, LOOK AT THE NIBBLE OF 200,000 shares bought just after the open today on the IHUB chart just above.
ANOTHER 6 MONTHS?
Invest do not trade....RADIO SILENCE FOR ME UNTIL CLRB BREAKS $2.25 PPS......
THE REALLLY BIG MONEY BUYS IN SIZE UPON REALIZATION (PROOF) CLRB IS THE REAL DEAL. FOR EXAMPLE, LOOK AT THE NIBBLE OF 200,000 shares bought just after the open today on the IHUB chart just above.
ANOTHER 6 MONTHS?
Invest do not trade....RADIO SILENCE FOR ME UNTIL CLRB BREAKS $2.25 PPS......
Recent CLRB News
- Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 06/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/29/2026 12:50:22 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/28/2026 09:14:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2026 09:13:29 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/19/2026 09:05:41 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/18/2026 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 08:15:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 11:20:27 AM
- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 05/14/2026 11:15:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 11:00:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 12:07:18 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/11/2026 11:05:22 PM
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 • GlobeNewswire Inc. • 05/11/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 10:04:31 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2026 03:48:39 PM
- Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia • IH Market News • 05/05/2026 02:21:30 PM
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia • GlobeNewswire Inc. • 05/05/2026 11:10:00 AM
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:51:51 PM
- Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 • GlobeNewswire Inc. • 04/21/2026 02:00:00 PM
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) • GlobeNewswire Inc. • 04/14/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 12:23:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 12:21:32 PM
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates • GlobeNewswire Inc. • 03/04/2026 12:15:00 PM
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 • GlobeNewswire Inc. • 02/25/2026 01:05:00 PM
